Camber Pharmaceuticals announced today that the FDA has approved ANDA 207022 for Mycophenolate Mofetil, marking a new entry into the market for the immunosuppressant. This approval strengthens Camber’s generics portfolio and is expected to enhance generic competition, offering potential cost savings for patients and payers.